Dana-Farber Cancer Institute celebrates passage of the Accelerating Kids’ Access to Care Act by the U.S. House of Representatives
Laurie Glimcher shared on X:
“Dana-Farber Cancer Institute celebrates passage of the Accelerating Kids’ Access to Care Act by the U.S. House of Representatives.
Thank you to Lori Trahan for her leadership to help children enrolled in Medicaid and CHIP programs access lifesaving cancer care across state lines.”
Source: Laurie Glimcher/LinkedIn
Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947. Currently, the Institute has over 5,000 staff, faculty, and clinicians on board.
They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.
As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.
Laurie H. Glimcher is the CEO of Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor of Medicine at Harvard Medical School.
Previously, she was the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs at Cornell University. Her research identified critical transcriptional regulators of immune responses in autoimmune, infectious, and malignant diseases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023